Charles E. Schmidt College of Medicine, Florida Atlantic University , Boca Raton, Florida, USA.
Department of Clinical Genomics, Atwal Clinic , Jacksonville, Florida, USA.
Ophthalmic Genet. 2020 Dec;41(6):563-569. doi: 10.1080/13816810.2020.1814344. Epub 2020 Sep 17.
Autosomal Dominant Optic Atrophy (ADOA) is caused by mutations in the Optic Atrophy 1 Gene which disrupts the OPA1 protein. This disruption affects the normal function of the protein; impairs fusion of the mitochondrial inner membrane; and prevents normal OPA1 protein degradation. These events cause damage in retinal ganglion cells that could affect the patients with symptoms ranging from none to legally blind.
Our study identifies a missense variant mutation, c.1024 A > G (p.K342E), in gene causing ADOA. Diagnosed clinically in three family members and the presence of this mutation was confirmed in two members by genetic testing. Pathogenic variants in OPA1 impact the secondary protein structure and function by causing non-conservative amino acid substitutions. We also modeled this mutation and compared it to the wild type using statistical mechanics.
The proband's pathogenic variant, c.1024 A > G (p.K342E), is located in the GTPase domain of OPA1 and causes changes in the protein structure by affecting the oligomerization pattern thus resulting in ADOA. Identifying the pathogenic potential of the missense mutations in the OPA1 gene using neoteric protein modeling techniques would help in the early detection of ADOA in patients who have family history of blindness. This action would help in providing early follow up, possible treatment in the future, and genetic counseling. ADOA: Autosomal Dominant Optic Atrophy; CYCS: Caspase Activator Cytochrome C; OPA1: Optic Atrophy Gene 1; RGC: Retinal Ganglion Cells; VUS: Variant of Uncertain Significance.
常染色体显性视神经萎缩(ADOA)是由 Optic Atrophy 1 基因的突变引起的,该突变会破坏 OPA1 蛋白。这种破坏会影响蛋白质的正常功能;干扰线粒体内膜的融合;并阻止正常的 OPA1 蛋白降解。这些事件会导致视网膜神经节细胞受损,从而影响患者的症状,从无症状到法定失明不等。
我们的研究确定了一个错义变异突变,c.1024 A > G(p.K342E),在导致 ADOA 的基因中。在三个家庭成员中进行了临床诊断,并且在两个家庭成员中通过基因测试证实了该突变的存在。OPA1 中的致病变体通过引起非保守氨基酸取代来影响二级蛋白质结构和功能。我们还使用统计力学对该突变进行建模,并与野生型进行了比较。
先证者的致病性变异,c.1024 A > G(p.K342E),位于 OPA1 的 GTPase 结构域,通过影响寡聚化模式导致蛋白质结构发生变化,从而导致 ADOA。使用新的蛋白质建模技术识别 OPA1 基因中的错义突变的致病性潜力,将有助于在有失明家族史的患者中早期发现 ADOA。这一行动将有助于提供早期随访、未来可能的治疗和遗传咨询。ADOA:常染色体显性视神经萎缩;CYCS:半胱天冬酶激活细胞色素 C;OPA1:视神经萎缩基因 1;RGC:视网膜神经节细胞;VUS:意义不确定的变异。